glp-1 drug least chemical modification GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous production and L-cell differentiation | Diabetology & Metabolic Syndrome Frontiers | GLP-1R in diabetes

Wilding et al

GLP-1 RAs provide pharmacologic levels of GLP-1 which reduces glucose and weight by increasing glucose-dependent insulin secretion and decreasing glucagon secretion, delaying gastric emptying and increasing satiety

CONCLUSION Initially, GLP-1RAs were designed for the treatment of metabolic disorders such as type 2 diabetes and obesity, new data suggest that these drugs tend to also express anti-inflammatory characteristics by modulation and down-regulating the immune response driven by the body

FDA-approved titration schedules typically involve 4-8 week intervals between dose increases, allowing physiological adaptation to occur